Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.
Recent performance snapshot for Novo Nordisk (NVO)
With no single headline event driving the move, Novo Nordisk (NVO) has drawn attention after a mixed stretch for the stock, including a gain of about 10% over the past month alongside weaker longer term returns.
See our latest analysis for Novo Nordisk.
Recent trading paints a mixed picture, with the share price up about 10% over the past month yet down over longer horizons, including a year to date decline of 14.6% and a 1 year total shareholder return decline of 28.21%. This hints that short term momentum is building after a weaker multi year stretch.
If Novo Nordisk’s recent moves have you reassessing healthcare exposure, it can be useful to scan for other opportunities using a screener focused on 32 healthcare AI stocks
So with Novo Nordisk trading close to analyst targets despite recent share price pressure and only moderate revenue and net income growth, should you see lingering value here, or assume the market is already pricing in future growth?
Most Popular Narrative: 52.9% Undervalued
According to the most followed narrative on Novo Nordisk, a fair value of about $95 per share sits well above the last close of $44.74, which frames the current price as a deep discount.
With durable economics, undervalued optionality, and long-duration growth potential, Novo Nordisk stands as a high-quality compounder available at a rare discount. In a market lacking margin resilience, Novo offers both growth and ballast.
Want to see what is baked into that $95 fair value? The narrative leans heavily on resilient margins, steady top line expansion and a future earnings multiple that assumes the GLP 1 franchise keeps delivering over many years. Curious which revenue and margin paths have to hold for that to stack up?
Result: Fair Value of $95 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, this upside story could be challenged by tougher GLP 1 competition and sustained US pricing pressure, which continues to weigh on growth guidance and profit margins.
Find out about the key risks to this Novo Nordisk narrative.
Next Steps
With sentiment split between risks and rewards, it makes sense to look at the numbers yourself, act while the data is fresh, and weigh the 3 key rewards and 3 important warning signs.
Looking for more investment ideas?
If Novo Nordisk has sharpened your focus, do not stop here. Fresh ideas across sectors can help you build a stronger, more resilient portfolio over time.